Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Semaglutide in Overweight/Obese Adults With Cystic Fibrosis-related Diabetes
NCT05788965Phase 3Completed
- Sponsor
- University of Minnesota
- Start
- Oct 2023
- Primary completion
- Dec 2024
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of semaglutide in cystic fibrosis-related diabetes (CFRD), obesity, sponsored by University of Minnesota. Started Oct 2023; status: completed.
02
Drugs
03
Conditions
cystic fibrosis-related diabetes (CFRD)obesity
Beyond the preview
Go deeper on NCT05788965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788965.